Critique Examines Causal Link Between GLP-1 Agonists and Vision Loss

GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide and liraglutide, are highly effective medications widely used for managing type 2 diabetes and obesity. Recently, concerns have emerged regarding a potential association with non-arteritic anterior ischaemic optic neuropathy (NAION), a condition characterized by sudden, painless vision loss due to insufficient blood flow to the optic nerve. This critique systematically evaluates the existing clinical evidence to determine if a direct causal relationship can be established between GLP-1 RAs and the development of NAION.

The critique found that while individual cases of NAION have been reported in patients receiving GLP-1 RAs, the overall reported incidence remains exceedingly low, estimated at less than 0.01% across large patient cohorts. Analysis of available data revealed no statistically significant increase in NAION risk among GLP-1 RA users when compared to control groups or the background population incidence (p>0.05). Many reported cases of NAION in patients on GLP-1 RAs also presented with established vascular risk factors for the condition, such as hypertension or diabetes, making it challenging to isolate the drug's specific contribution. > The most critical finding was that the current body of clinical evidence, primarily derived from observational studies and spontaneous adverse event reports, is insufficient to establish a direct causal link between GLP-1 receptor agonists and non-arteritic anterior ischaemic optic neuropathy. The temporal relationship between drug initiation and NAION onset was inconsistent, further complicating the attribution of causality.